Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives

Journal of Medicinal Chemistry

Volumn 40, Issue 12, 1997, Pages 1863-1869

  Kaneko, Masami ^a   Saito, Yutaka ^a   Saito, Hiromitsu ^a   Matsumoto, Tadashi ^a   Matsuda, Yuzuru ^a   Vaught, Jeffry L ^b   Dionne, Craig A ^b   Angeles, Thelma S ^b   Glicksman, Marcie A ^b   Neff, Nicola T ^b   Rotella, David P ^b   Kauer, James C ^b   Mallamo, John P ^b   Hudkins, Robert L ^b   Murakata, Chikara ^a,b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,9 BIS[(ETHYLTHIO)METHYL] K252A; CHOLINE ACETYLTRANSFERASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; K 252A; MYOSIN LIGHT CHAIN KINASE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; PROTEIN KINASE C; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CELL DEATH; CHOLINERGIC NERVE CELL; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; MOTONEURON; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; NEUROTROPISM; OLIVARY NUCLEUS; SPINAL NERVE;

ANIMALS; APOPTOSIS; CARBAZOLES; CHICK EMBRYO; CHOLINE O-ACETYLTRANSFERASE; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MOTOR NEURONS; NERVE DEGENERATION; NERVE GROWTH FACTORS; NEURONS; PROSENCEPHALON; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, TRKA; RECEPTORS, NERVE GROWTH FACTOR; SPINAL CORD; SUBSTANTIA INNOMINATA;

EID: 15144358619     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970031d     Document Type: Article

References (43)

1. (a) DiStefano, P. Pharmacology of neurotrophic factors in models of neurodegenerative diseases. Annu. Rep. Med. Chem. 1993, 28, 11-17.
2. (b) Barde, Y.-A. Trophic factors and neuronal survival. Neuron 1989, 2, 1525-1534.
3. (c) Alderson, R. F. Brain derived neurotrophic factor increase survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 1990, 5, 279-306.
4. (d) Collazo, D.; Takahashi, H.; McKay, R. D. G. Cellular targets and trophic functions of neurotrophin-3 in the developing rat hippocampus. Neuron 1992, 9, 643-656.
5. Thoenen, H.; Barde, Y. A. Physiology of nerve growth factor. Physiol. Rev. 1980, 60, 1284-1335.
6. Hartikka, K. J.; Hefti, F. Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth and expression of transmitter-specific enzymes. J. Neurosci. 1988, 8, 2967-2985.
7. (a) Lewis, M. E.; Neff, N. T.; Contreras, P. C.; Stong, D. B.; Oppenheim, R. W.; Grebow, P. E.; Vaught, J. L. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol. 1993, 124, 73-88.
8. (b) Neff, N. T.; Prevette, D.; Houenou, L. J.; Lewis, M. E.; Glicksman, M. A.; Yin, Q. W.; Oppenheim, R. W. Insulin-like growth factors: Putative muscle derived trophic agents that promote motoneuron survival. J. Neurobiol. 1993, 24, 1578-1588.
9. Seiger, A.; Nordberg, A.; vonHolst, H.; Backman, L.; Ebendal, L.; Alafuzoff, I.; Ambria, K.; Herlitz, A.; Lilja, A. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behav. Brain Res. 1993, 57, 255-261.
10. Kratz, R.; Felice, K. J.; Gamell, M. J.; Gelinas, D.; Lai, E. C.; Lange, D. J.; Natter, H. M.; Rudnicki, S.; Miller, K.; Murphy, M. F. Evaluation of the treatment effect of recombinant human insulin-like growth factor-1 on health related quality of life in patients with amyotrophic lateral sclerosis. Neurology 1996, 46 (2 Suppl.).
11. Saltiel, A. R.; Decker, S. J. Cellular mechanism of signal transduction for neurotrophins. BioEssays 1994, 16, 405-411.
12. (a) Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R. J.; Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270, 1326-1331.
13. (b) Ham J.; Babij, C.; Whitfield, J.; Pfarr, C. M.; Lallemand, D.; Yaniv, M.; Rubin, L. L. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 1995, 14, 929-939.
14. Kase, H.; Iwahashi, K.; Matsuda, Y. K-252a, A potent inhibitor of protein kinase C from microbial origin. J. Antibiot. (Tokyo) 1986, 39, 1059-1065.
15. Kase, H.; Iwahashi, K.; Nakanishi, S.; Matsuda, Y.; Yamada, K.; Takahashi, M.; Murakata, C.; Sato, A.; Kaneko, M. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 1987, 142, 436-440.
16. Knusel, B.; Hefti, F. K-252 compounds: modulators of neurotrophic signal transduction. J. Neurochem. 1992, 59, 1987-1996.
17. Maroney, A. C.; Lipfert, L.; Forbes, M. E.; Glicksman, M. A.; Neff, N. T.; Siman, R.; Dionne, C. A. K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells. J. Neurochem. 1995, 64, 540-549.
18. Borasio, G. D. Differential effects of the protein kinase inhibitor K-252a on the in vitro survival of chick embryonic neurons. Neurosci. Lett. 1990, 108, 207-212.
19. Glicksman, M. A.; Prantner, J. E.; Meyer, S. L.; Forbes, M. E.; Dasgupta, M.; Lewis, M. E.; Neff, N. T. K-252a and staurosporine promote choline acetyltransferase activity in rat spinal cord culture. J. Neurochem. 1993, 61, 210-221.
20. Glicksman, M. A.; Forbes, M. E.; Prantner, J. E.; Neff, N. T. K-252a promotes survival and choline acetyltransferase activity in striatal and basal forebrain neuronal cultures. J. Neurochem. 1995, 64, 1502-1512.
21. Cheng, B.; Barger, S. W.; Mattson, M. P. Staurosporine, K-2S2a and K-252b stabilize calcium homeostasis and promote survival of CNS neurons in the absence of glucose. J. Neurochem. 1994, 62, 1319-1329.
22. Goodman, Y.; Mattson, M. P. Staurosporine and K-252a compounds protect hippocampal neurons against amyloid β-peptide toxicity and oxidative injury. Brain Res. 1994, 650, 170-174.
23. (a) Matsuda, Y.; Fukuda, J. Inhibition by K-252a, a new inhibitor of protein kinase, and of nerve growth factor-induced neurite outgrowth of chick embryo dorsal root ganglion cells. J. Neurosci. Lett. 1988, 256, 11-17.
24. (b) Hashimoto, S. K-252a, a potent protein kinase inhibitor, blocks nerve growth factor-induced neunte outgrowth and changes in the phosphorylation of proteins in PC12 cells. J. Cell Biol. 1988, 107, 1531-1539.
25. (a) Berg, M. M.; Sternberg, D. W.; Parada, L. F.; Chao, M. V. K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity. J. Biol. Chem. 1992, 267, 13-16.
26. (b) Tarpley, P.; Lamballe, F.; Barbacid, M. K-252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors. Oncogene 1992, 7, 371-381.
27. (c) Ohmichi, M.; Decker, S. J.; Pang, I.; Saltiel, A. R. Inhibition of the cellular actions of nerve growth factor by staurosporine and K-252a results from the attenuation of the activity of the trk tyrosine kinase. Biochemistry 1992, 31, 4034-4039.
28. (d) Muroya, K.; Hashimoto, Y.; Hattori, S.; Nakamuru, S. Specific inhibition of NGF receptor tyrosine kinase activity by K-252a. Biochim. Biophys. Acta 1992, 1135, 353-356.
29. (e) Nye, S. H.; Squinto, S. P.; Glass, D. J.; Stitt, T. N.; Hantzopoulos, P.; Macchi, M. J.; Lindsaay, N. S.; Ip, N. Y.; Yancopoulos, G. D. K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol. Biol. Cell 1992, 3, 677-683.
30. Angeles, T. S.; Steffler, C.; Bartlett, B. A.; Hudkins, R. L.; Stephens, R. M.; Kaplan, D. R.; Dionne, C. A. Enzyme linked immunosorbant assay for Trk A tyrosine kinase activity. Anal. Biochem. 1996, 236, 49-55.
31. Phelps, P. E.; Barber, R. P.; Vaughn, J. E. Generation patterns of four groups of cholinergic neurons in rat cervical spinal cord: a combined tritiated thymidine autoradiographic and choline acetyltransferase immunocytochemical study. J. Comp. Neurol. 1988, 273, 459-472.
32. (a) Oppenheim, R. W. The neurotrophic theory and naturally occuring motoneuron death. Trends Neurosci. 1989, 12, 252.
33. (b) Oppenheim, R. W. Cell death during developemnt of the nervous system. Annu. Rev. Neurosci. 1989, 14, 453-501.
34. (a) Glicksman, M. A.; Walton, K.; Basma, A.; Neff, N.; Dionne, C. A.; Maroney, A. C. Motoneurons undergoing apoptosis have increased JNK1 (SAPK) activity but not ERK1 activity. Soc. Neurosci. Abstr. 1996, 22, 115.
35. (b) Glicksman, M. A.; Angeles, T. A.; Chiu, A. Y.; Dionne, C. A.; Dittrich, F.; Harty; Kaneko, M.; Maroney, A. C.; Matsuda, Y.; Murakata, C.; Oppenheim, R. W.; Prevette, D.; Sendter, M.; Sengelaub, D. R.; Vaught, J. L.; Neff, N. T. Unpublished results.
36. (c) Glicksman, M. A.; Neff, N. T.; Murakata, C.; Prevette, D.; Oppenheim, R. W.; Chiu, A. Y. A K-252a analog prevents developmentally programmed motoneuron death and the loss of ChAT activity in adult motoneurons in vivo. Soc. Neurosci. Abstr. 1994, 20, 441.
37. (d) Harty, M. W.; Glicksman, M. A.; Neff, N. T.; Murakata, C.; Sengelaub, D. R. In vivo effects of putative neurotrophic factors CEP1347, CNTF, and IGF-I in rescuing mammalian motoneurons from naturally occurring death. Soc. Neurosci. Abstr. 1995, 21, 1537.
38. Chu-Wang, L.-W.; Oppenheimer, R. W. Cell death of motoneurons in the chick embryo spinal cord. J. Comp. Neurol. 1978, 177, 33-58.
39. (a) Oppenheim, R. W.; Prevette, D.; Haverkamp, L. J.; Houenou, L.; Qin-Yei, Y.; McManaman, J. Biological studies of a putative avian muscle-derived neurotrophic factor that prevents naturally occuring motoneuron death in vivo. J. Neurobiol. 1993, 24, 1065-1079.
40. (b) Oppenheim, R. W.; Prevette, D.; Qin-Yei, Y.; Collins, F.; MacDonald, J. Control of embryonic motoneuron survival in vivo by ciliary neurotrophic factor. Science 1991, 251, 1616-1617.
41. Nordeen, E. J.; Nordeen, K. W.; Sengelaub, D. R.; Arnold, A. P. Androgens prevent normally occuring cell death in a sexually dimorphic spinal nucleus. Science 1985, 229, 671-673.
42. (a) Saporito, M. S.; Haun, F.; Brown, E.; DiCamillo, A.; Miller, M.; Murakata, C.; Neff, N.; Vaught, J. L.; Carswell, S. Rescue of cholinergic neurons in the nucleus basalis magnocellularis by the indolocarbazole CEP-1347. Unpublished results.
43. (b) Saporito, M. S.; Brown, E. R.; Haun, F.; Miller, M.; Murakata, C.; Neff, N. T.; Carswell, S. Comparison of the pharmacological actions of CEP-1347 to nerve growth factor with lesions of the nucleus basalis magnocellularis. Soc. Neurosci. Abstr. 1995, 21, 551.